Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis

Elvedin Osmanovic; Mersiha Cerkezovic; Almir Jagodic

doi:doi:10.11648/j.ajim.20221001.12

| Peer-Reviewed

Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis

Elvedin Osmanovic, Mersiha Cerkezovic, Almir Jagodic

Published in American Journal of Internal Medicine (Volume 10, Issue 1)

Received: 18 December 2021 Accepted: 5 January 2022 Published: 12 January 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythropoietin, which healthy kidneys excreted, and is necessary for hematopoiesis. Erythropoietin (EPO) is the main regulator of the daily production of red blood cells. EPO that is execrated by peritubular capillary membrane cells in the kidneys circulates within plasma in order to interact with target cells in the bone marrow to maintain or stimulate erythropoiesis. The main purpose of the action of EPO is the formation of erythroid colonies. During observation of differences in the ordination of EPO in each group between men and women, there is no statistical significance evident in the incidence of anemia before and after therapy, as in p=0.70. The target concentration of hemoglobin, which must be constantly maintained in people with chronic renal anemia, is 110-120 g/l, while the target value of the number of red blood cells is 4-5x10¹²/l and the hematocrit value is 0.35-4.5 l/l, with a slight outflow depending on the gender of the patient. The final values of the participants in our study treated with epoetin alpha show higher values of hemoglobin, hematocrit and erythrocytes, while the average values recorded in participants treated with darbepoetin decreased.

Published in	American Journal of Internal Medicine (Volume 10, Issue 1)
DOI	10.11648/j.ajim.20221001.12
Page(s)	8-12
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Erythropoietin, Hemodialysis, Erythrocytes, Hemoglobin, Hematocrit

References

[1]	Prkačin I, Klarić D, Lovčić V, Galešić K, Ilić M, Raki S. (2016). Russian experience in efficacy and safety of anemia correction in predialysis patients. Acta Med Croatica, Vol. 70 (Suppl. 2) 14-18.
[2]	Besarab A., Goodkin DA., Nissenson AR. (2008). Normal Hematocrit Cardiac Trial Authors. The normal hematocrit study--follow-up. N Engl J Med, 358: 433.
[3]	Melissa E. (2014). Prevalence of Anemia in Chronic Kidney Disease in the United States. Clinical Infectious Diseases, 28 (5), 55-60.
[4]	Winkelmayer W. (2015). Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. AJKD 66, 106-113.
[5]	Farrington K. et al. (2016). Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higer. Pharmacology reports, 12 (4), 13-15.
[6]	Kes P., Bašić N., Jukić I., Brunetta-Voronovic B. (2012) the Final stage of renal failure in the elderly. Acta med croatica, 66 (2): 22-36.
[7]	Gregory M. (2007). Cronic renal failure. Complex Pediatric Hospital of Medicine, 693-699.
[8]	Stauffer M., Tao F. (2014). Prevalence of Anemia in Chronic Kidney Disease in the United States. Plos one, 58-64.
[9]	Bubić I., Prkačin I., Rački S. (2012). Efficiency and safety of cera in the treatment of anemia in predialysis patients, Croatian experience. Acta med croatica, 66 (2), 42-46.
[10]	Palmer SC., Navaneethan SD., Craig JC., et al. (2010). Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med, 153: 23.
[11]	Clement FM., Klarenbach S., Tonelli M., et al. (2009). The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med, 169: 1104.
[12]	Coyne DW. (2012). The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int, 82: 235.
[13]	Nissenson AR., Swan SK., Lindberg JS., et al. (2002). Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis, 40: 110.
[14]	Tolman C., Richardson D., Bartlett C., Will E. (2005). Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol, 16: 1463.
[15]	Weiner DE., Miskulin DC., Seefeld K. et al. (2007). Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol 2007, 18: 3184.

Cite This Article

Plain Text BibTeX RIS

APA Style

Elvedin Osmanovic, Mersiha Cerkezovic, Almir Jagodic. (2022). Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis. American Journal of Internal Medicine, 10(1), 8-12. https://doi.org/10.11648/j.ajim.20221001.12

Copy | Download

ACS Style

Elvedin Osmanovic; Mersiha Cerkezovic; Almir Jagodic. Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis. Am. J. Intern. Med. 2022, 10(1), 8-12. doi: 10.11648/j.ajim.20221001.12

Copy | Download

AMA Style

Elvedin Osmanovic, Mersiha Cerkezovic, Almir Jagodic. Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis. Am J Intern Med. 2022;10(1):8-12. doi: 10.11648/j.ajim.20221001.12

Copy | Download

@article{10.11648/j.ajim.20221001.12,
  author = {Elvedin Osmanovic and Mersiha Cerkezovic and Almir Jagodic},
  title = {Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis},
  journal = {American Journal of Internal Medicine},
  volume = {10},
  number = {1},
  pages = {8-12},
  doi = {10.11648/j.ajim.20221001.12},
  url = {https://doi.org/10.11648/j.ajim.20221001.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20221001.12},
  abstract = {One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythropoietin, which healthy kidneys excreted, and is necessary for hematopoiesis. Erythropoietin (EPO) is the main regulator of the daily production of red blood cells. EPO that is execrated by peritubular capillary membrane cells in the kidneys circulates within plasma in order to interact with target cells in the bone marrow to maintain or stimulate erythropoiesis. The main purpose of the action of EPO is the formation of erythroid colonies. During observation of differences in the ordination of EPO in each group between men and women, there is no statistical significance evident in the incidence of anemia before and after therapy, as in p=0.70. The target concentration of hemoglobin, which must be constantly maintained in people with chronic renal anemia, is 110-120 g/l, while the target value of the number of red blood cells is 4-5x1012/l and the hematocrit value is 0.35-4.5 l/l, with a slight outflow depending on the gender of the patient. The final values of the participants in our study treated with epoetin alpha show higher values of hemoglobin, hematocrit and erythrocytes, while the average values recorded in participants treated with darbepoetin decreased.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis
AU  - Elvedin Osmanovic
AU  - Mersiha Cerkezovic
AU  - Almir Jagodic
Y1  - 2022/01/12
PY  - 2022
N1  - https://doi.org/10.11648/j.ajim.20221001.12
DO  - 10.11648/j.ajim.20221001.12
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 8
EP  - 12
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20221001.12
AB  - One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythropoietin, which healthy kidneys excreted, and is necessary for hematopoiesis. Erythropoietin (EPO) is the main regulator of the daily production of red blood cells. EPO that is execrated by peritubular capillary membrane cells in the kidneys circulates within plasma in order to interact with target cells in the bone marrow to maintain or stimulate erythropoiesis. The main purpose of the action of EPO is the formation of erythroid colonies. During observation of differences in the ordination of EPO in each group between men and women, there is no statistical significance evident in the incidence of anemia before and after therapy, as in p=0.70. The target concentration of hemoglobin, which must be constantly maintained in people with chronic renal anemia, is 110-120 g/l, while the target value of the number of red blood cells is 4-5x1012/l and the hematocrit value is 0.35-4.5 l/l, with a slight outflow depending on the gender of the patient. The final values of the participants in our study treated with epoetin alpha show higher values of hemoglobin, hematocrit and erythrocytes, while the average values recorded in participants treated with darbepoetin decreased.
VL  - 10
IS  - 1
ER  -

Copy | Download

Author Information

Elvedin Osmanovic

Hemodialysis Center, Public Health Institution Health Centre Zivinice, Bosnia and Herzegovina
Mersiha Cerkezovic

Hemodialysis Center, Public Health Institution Health Centre Zivinice, Bosnia and Herzegovina
Almir Jagodic

Department of Physical Medicine and Rehabilitation, Public Health Institution Health Center Zivinice, Bosnia and Herzegovina

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Elvedin Osmanovic, Mersiha Cerkezovic, Almir Jagodic. (2022). Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis. American Journal of Internal Medicine, 10(1), 8-12. https://doi.org/10.11648/j.ajim.20221001.12

Copy | Download

ACS Style

Elvedin Osmanovic; Mersiha Cerkezovic; Almir Jagodic. Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis. Am. J. Intern. Med. 2022, 10(1), 8-12. doi: 10.11648/j.ajim.20221001.12

Copy | Download

AMA Style

Elvedin Osmanovic, Mersiha Cerkezovic, Almir Jagodic. Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis. Am J Intern Med. 2022;10(1):8-12. doi: 10.11648/j.ajim.20221001.12

Copy | Download

@article{10.11648/j.ajim.20221001.12,
  author = {Elvedin Osmanovic and Mersiha Cerkezovic and Almir Jagodic},
  title = {Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis},
  journal = {American Journal of Internal Medicine},
  volume = {10},
  number = {1},
  pages = {8-12},
  doi = {10.11648/j.ajim.20221001.12},
  url = {https://doi.org/10.11648/j.ajim.20221001.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20221001.12},
  abstract = {One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythropoietin, which healthy kidneys excreted, and is necessary for hematopoiesis. Erythropoietin (EPO) is the main regulator of the daily production of red blood cells. EPO that is execrated by peritubular capillary membrane cells in the kidneys circulates within plasma in order to interact with target cells in the bone marrow to maintain or stimulate erythropoiesis. The main purpose of the action of EPO is the formation of erythroid colonies. During observation of differences in the ordination of EPO in each group between men and women, there is no statistical significance evident in the incidence of anemia before and after therapy, as in p=0.70. The target concentration of hemoglobin, which must be constantly maintained in people with chronic renal anemia, is 110-120 g/l, while the target value of the number of red blood cells is 4-5x1012/l and the hematocrit value is 0.35-4.5 l/l, with a slight outflow depending on the gender of the patient. The final values of the participants in our study treated with epoetin alpha show higher values of hemoglobin, hematocrit and erythrocytes, while the average values recorded in participants treated with darbepoetin decreased.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis
AU  - Elvedin Osmanovic
AU  - Mersiha Cerkezovic
AU  - Almir Jagodic
Y1  - 2022/01/12
PY  - 2022
N1  - https://doi.org/10.11648/j.ajim.20221001.12
DO  - 10.11648/j.ajim.20221001.12
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 8
EP  - 12
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20221001.12
AB  - One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythropoietin, which healthy kidneys excreted, and is necessary for hematopoiesis. Erythropoietin (EPO) is the main regulator of the daily production of red blood cells. EPO that is execrated by peritubular capillary membrane cells in the kidneys circulates within plasma in order to interact with target cells in the bone marrow to maintain or stimulate erythropoiesis. The main purpose of the action of EPO is the formation of erythroid colonies. During observation of differences in the ordination of EPO in each group between men and women, there is no statistical significance evident in the incidence of anemia before and after therapy, as in p=0.70. The target concentration of hemoglobin, which must be constantly maintained in people with chronic renal anemia, is 110-120 g/l, while the target value of the number of red blood cells is 4-5x1012/l and the hematocrit value is 0.35-4.5 l/l, with a slight outflow depending on the gender of the patient. The final values of the participants in our study treated with epoetin alpha show higher values of hemoglobin, hematocrit and erythrocytes, while the average values recorded in participants treated with darbepoetin decreased.
VL  - 10
IS  - 1
ER  -

Copy | Download